Wogonin

• CAT Number: I004386
• CAS Number: 632-85-9
• Molecular Formula: C16H12O5
• Molecular Weight: 284.30
• Purity: ≥95%
• Synonyms: BRN 0287152
• Solubility: DMSO 10 mg/ml
• Storage: -20°C

Wogonin（Cat No.:I004386）is a naturally occurring flavonoid derived from the roots of Scutellaria baicalensis, known for its anti-inflammatory, antioxidant, and anticancer properties. It exerts its effects by modulating various signaling pathways, including the inhibition of NF-κB, induction of apoptosis, and suppression of pro-inflammatory cytokines. Wogonin has been extensively studied for its potential in cancer research, where it promotes tumor cell death while sparing normal cells. Additionally, its neuroprotective and anti-anxiety effects make it a promising candidate for neurological and anti-inflammatory therapies.

Reference

[1]. He L, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/β-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013 Oct 4;312:36-47.
[2]. Zhu Y, et al. Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: potential drug to treat Alzheimer/’s disease. Neurol Sci. 2015 Jan 18.
[3]. Chen S, et al. Wogonin Inhibits LPS-Induced Inflammatory Responses in Rat Dorsal Root Ganglion Neurons Via Inhibiting TLR4-MyD88-TAK1-Mediated NF-κB and MAPK Signaling Pathway. Cell Mol Neurobiol. 2014 Dec 14.
[4]. Kwak S, et al. Vascular barrier protective effects of baicalin, baicalein and wogonin in vitro and in vivo. Toxicol Appl Pharmacol. 2014 Sep 16;281(1):30-38.
[5]. Yang H, et al. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. Oncotarget. 2014 Sep 30;5(18):8188-201.
[6]. Yao J, et al. Wogonin prevents lipopolysaccharide-induced acute lung injury and inflammation in mice via peroxisome proliferator-activated receptor gamma-mediated attenuation of the nuclear factor-kappaB pathway. Immunology. 2014 Oct;143(2):241-57.